Corpus ID: 30341934

Effects of triflusal in patients with prosthetic heart valves.

  title={Effects of triflusal in patients with prosthetic heart valves.},
  author={Mar{\'i}a Jes{\'u}s Dom{\'i}nguez and Marta Vacas and Yolanda S{\'a}ez and I Olabarr{\'i}a and Aila V. Velasco and Jos{\'e} Antonio Iriarte and Javier Forn},
  journal={Clinical therapeutics},
  volume={7 3},
The biological effects of a new antiplatelet agent, triflusal, were evaluated in patients with cardiac valvular prostheses. Each patient received 900 mg/day of oral triflusal for 30 days. Triflusal significantly inhibited platelet aggregation induced by adenosine diphosphate (1 to 5 mumol) or epinephrine (12.5 mumol), showing a slight effect on bleeding time (basal: 6 +/- 1.7 min; 30 days of treatment: 8.0 +/- 2.7 min). Serum levels of thromboxane B2 were significantly reduced during treatment… Expand
Effects of triflusal and acetylsalicylic acid on platelet aggregation in whole blood of diabetic patients
A study was made on the inhibitory effect of triflusal and acetylsalicylic acid on platelet aggregation in whole blood and platelet‐rich plasma induced by ADP, in 30 insulin‐dependent diabetic patients without vascular complications. Expand
Triflusal versus Aspirin for the Prevention of Stroke
The TAPIRSS study contributed evidence on the efficacy and safety of triflusal as a valid alternative to aspirin in the prevention of vascular events in patients with ischemic stroke or TIA. Expand
Prevention of the formation of arterial thrombi using different antiplatelet drugs: experimental study in dogs.
The formation of arterial thrombosis in dogs was induced by means of an intima lesion produced by continuous current and the only effective treatment was that employed in Group II (p less than 0.05). Expand
Effect of treatment with an inhibitor of platelet aggregation on the evolution of background retinopathy: 2 years of follow-up.
The results suggest that platelet antiaggregant therapy can be useful in the treatment of background diabetic retinopathy. Expand
Does antiplatelet therapy increase the risk of hemoptysis during percutaneous transthoracic needle biopsy of a pulmonary lesion?
Single-antiplatelet therapy suspended for less than 10 days is not an independent risk factor for the occurrence of PTNB-related hemoptysis, whereas dual-antiplateslet therapy increases its risk. Expand
Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness.
Aspirin remains the first choice and should be combined with clopidogrel, which can substitute for aspirin in case the latter is contraindicated, for thromboprophylaxis in patients with atrial fibrillation and in patients at low risk for stroke. Expand
Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose
A rapid absorption of triflusal and an immediate biotransformation into HTB are obtained, which could be explained by the irreversible inhibition of platelet cyclo-oxygenase and the sustained levels of HTB, which also possess anti-aggregant properties. Expand
Pharmacokinetics of triflusal and its main metabolite in rats and dogs
A new analytical technique based on HPLC was developed that enabled us to carry out a pharmacokinetic study of the drug triflusal and its metabolite in animals and indicated an important first pass effect. Expand
Binding of a metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic acid) to serum proteins in rat and man
2-hydroxy-4-trifluoromethylbenzoic acid is the main active metabolite of the platelet anti-aggregant drug triflusal and had high affinity for plasma albumin, which was not saturable after therapeutic doses. Expand
Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers
ObjectiveTriflusal has been shown to exert neuroprotective effects by downregulating molecules considered responsible for the development of Alzheimer’s disease (AD). The aim of this study was toExpand